A5088620662- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Acute Ischemic Stroke Management
- Cardiac electrophysiology and arrhythmias
- Photochromic and Fluorescence Chemistry
- Acute Myocardial Infarction Research
- Liquid Crystal Research Advancements
- Cerebrovascular and Carotid Artery Diseases
- Cardiac Imaging and Diagnostics
- Various Chemistry Research Topics
- Polydiacetylene-based materials and applications
- Dyeing and Modifying Textile Fibers
- Photopolymerization techniques and applications
- Blood Pressure and Hypertension Studies
- Conducting polymers and applications
- Health Systems, Economic Evaluations, Quality of Life
University of Eastern Finland
2024-2025
Aalto University
2017-2023
Abstract Background Direct oral anticoagulants (DOACs) at reduced dosage regimens are the first choice of ischaemic stroke (IS) prevention for patients with atrial fibrillation (AF) and elevated bleeding risk or renal insufficiency. We compared outcomes dose DOACs warfarin. Methods results included all new-onset AF in Finland from 2011 to 2018. Adjusted hazard ratios (HR) IS, intracranial haemorrhage (ICH), bleeding, mortality were calculated dabigatran (n=2 672), rivaroxaban (n=1 866),...
Abstract Low socioeconomic status has been associated with poor outcomes in patients atrial fibrillation (AF). However, little is known about disparities adherence to stroke prevention direct oral anticoagulants (DOACs). We assessed the hypothesis that AF higher income or educational levels have better DOACs terms of treatment implementation and persistence. The used nationwide registry‐based FinACAF cohort covers all incident starting Finland during 2011–2018. analyses included 74 222 (mean...
Abstract Aims Elective cardioversion (ECV) is routinely used in atrial fibrillation (AF) to restore sinus rhythm. However, it includes a risk of thromboembolism even during adequate oral anticoagulation treatment. The aim this study was evaluate the thromboembolic and bleeding complications after ECV real-life setting utilizing data from large AF population. Methods results This nationwide register-based included all (n = 9625) Finnish patients undergoing their first-ever between 2012 2018....
Little is known how individual time-in-therapeutic-range (TTR) impacts the effectiveness and safety of warfarin therapy compared to direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF).
In recent years, supramolecular complexes comprising a poly(4-vinylpyridine) backbone and azobenzene-based halogen bond donors have emerged as promising class of materials for the inscription light-induced surface-relief gratings (SRGs). The studies up to date focused on building hierarchies, i.e., optimizing polymer-azobenzene noncovalent interaction efficient surface patterning. They been conducted using systems with relatively low azobenzene content, little is known about concentration...
Abstract Background Direct oral anticoagulants (DOACs) have largely replaced warfarin as the primary choice of anticoagulation (OAC) in atrial fibrillation (AF) patients. This study uses a nationwide registry data set to compare health and social care costs AF patients using different OAC therapies. We studied how these were distributed among services year following onset develop time before after diagnosis. Methods is part Finnish AntiCoagulation Atrial Fibrillation (FinACAF) research...
Abstract Background Patients with atrial fibrillation (AF) undergoing cardioversion (CV) are exposed to an increased risk for stroke during the post-cardioversion period, but exact magnitude of this after elective CV preceding appropriate oral anticoagulant (OAC) therapy is unknown. Purpose We explored rate ischaemic (IS) and compared IS period long-term in patients AF using guideline-recommended OAC therapy. Methods This a nationwide register-based study, including all their first-ever...
Abstract Funding Acknowledgements Type of funding sources: Public hospital(s). Main source(s): Helsinki and Uusimaa Hospital District TYH2019309 The Finnish Foundation for Cardiovascular Research Background/Introduction Acute myocardial infarction (AMI) atrial fibrillation (AF) are commonly seen in a same patient. It is not unusual that patients diagnosed with new-onset AF as complication AMI. Nevertheless, little known about the temporal relations these two diagnoses. Purpose We evaluated...
Abstract Background and aims Direct oral anticoagulants (DOACs) have almost replaced warfarin in stroke prevention of patients with atrial fibrillation (AF). However, little is known whether DOACs are more efficacious or safer than having information on time-in-therapeutic-range (TTR) the warfarin-treated patients. Methods The Finnish AntiCoagulation Atrial Fibrillation (FinACAF) a nationwide study AF combining data from several health care registers. We analyzed all new-onset 2011 to 2018...
Abstract Background and purpose Oral anticoagulation (OAC) is the cornerstone of thromboprophylaxis in atrial fibrillation (AF) yet complicated by elevated bleeding risk. We examined temporal evolution OAC treatment on 30-day fatality patients with AF first-ever hemorrhagic stroke (HS). Methods identified study population from nationwide registry-linking Finnish AntiCoagulation Atrial Fibrillation (FinACAF) study. Patients were eligible if incident was diagnosed between January 2009 November...
Abstract Background and aims Direct oral anticoagulants (DOACs) have replaced Vitamin-K antagonists as the primary choice of anticoagulation (OAC) in atrial fibrillation (AF). However, after several years experience with DOACs, no studies been made comparing efficacy safety reduced dose DOACs warfarin when quality treatment (time therapeutic range, TTR) information is available. Methods The Finnish AntiCoagulation Atrial Fibrillation (FinACAF) a nationwide study AF patients combining data...
Background and Aims: The risk of ischemic stroke associated with atrial fibrillation (AF) can be reduced oral anticoagulation therapy (OAC). We examined the patient characteristics nationwide use OACs in primary secondary care AF patients. Methods: Finnish AntiCoagulation Atrial Fibrillation (FinACAF) -study is a study patients that combines data from several health registers. In this all new-onset Finland January 2011 to December 2018 laboratory were analyzed. Comorbidities CHA 2 DS -VASc...